PharmaRadar360

PharmaRadar360

NeurologyDrug intelligence

Leqembi

Lecanemab

Amyloid beta-directed antibody. Developed by Eisai. Clinical, regulatory, and source evidence are connected below.

Company
Eisai
Target / MOA
Amyloid beta
Aliases
Leqembi 路 BAN2401
Signals
8
Clinical trials
5
Approvals
1
Evidence sources
8

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

regulatory eventFDA Drug Approvals

FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer鈥檚 disease taking Leqembi (lecanemab)

FDA to recommend additional, earlier MRI monitoring for patients with Alzheimer鈥檚 disease taking Leqembi (lecanemab)

clinical trialClinicalTrials.gov

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

N/A 路 RECRUITING 路 Emory University

clinical trialClinicalTrials.gov

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Phase 2 路 ACTIVE_NOT_RECRUITING 路 Eisai Inc.

Clinical trials

Key active studies

A focused view of recently updated studies 路 5 linked records.

N/ARECRUITINGNCT05999084

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

Emory University 路 Updated Mar 11, 2026

Phase 2ACTIVE NOT RECRUITINGNCT06602258

A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

Eisai Inc. 路 Updated Feb 11, 2026

EARLY/Phase 1ACTIVE NOT RECRUITINGNCT05469009

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

Ali Rezai 路 Updated Jan 22, 2026

Phase 4ACTIVE NOT RECRUITINGNCT07034222

12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

Ruijin Hospital 路 Updated Jun 24, 2025

N/ARECRUITINGNCT06400368

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

NeuroVision Imaging 路 Updated May 7, 2024

Related intelligence

Connected drugs

Records connected through the current intelligence graph.

VyvgartEfgartigimod 路 argenx 路 Neurology

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial 路 Latest Mar 11, 20265FDA Drug Approvalsofficial 路 Latest Apr 3, 20261FDAofficial 路 Latest Jan 24, 20251
Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.